Absci, a Vancouver-based startup, is the latest Washington biotech company to announce its intent to go public. The company has had a robust 2021 so far, acquiring two companies to further build out its capabilities as well as multiple investments totaling in the multimillion-dollar range.
Absci develops technologies to accelerate the process of drug discovery using a platform that is built to design and generate protein-based drug candidates and help screen them for optimal functioning. Founded in 2011, it began commercial operations in 2018 and now has partnerships with Merck, Xyphos Biotechnology, Alpha Cancer Technologies and several other companies.